원문정보
초록
영어
The recombinant production of therapeutic proteins from transgenic animal is the major technology of animal biotechnology and is one of the biggest challenges in an efficient bioreactor in the pharmaceutical industry. The useful gene delivery into cells or animals is an important way to express the target gene in mammary glands. Tissue plasminogen activator (tPA) is known to play an important role in the major enzyme responsible for blood clots breakdown. Because it works on the clotting system, tPA is used in clinical medicine to treat thrombolysis, such as pulmonary embolism, myocardial infraction and stroke. The objective of this study is a production of recombinant human tPA protein in the milk of porcine. For this study, we construct knock-in vector that human tPA gene is inserted into the exon 1 locus of porcine whey acid protein (pWAP) gene knock-out somatic cell by homologous recombination. Finally, establishment of tPA knock-in cell lines were confirmed by genomic PCR analysis and identification of karyotype. As a result, we established cell lines of pWAP knock-out expressing human tPA gene from porcine fibroblasts to apply somatic cell nuclear transfer (SCNT). Further study will be performed for the production of transgenic pigs.